‹ ›
MYP_071786
← PREVIOUS NEXT → BACK
Basic Information
CPM
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
7 amino acids
C42H61N7O8S2
Standard
Sequence
CPFVFLM
Physicochemical Analysis
856.11 Da
5.52
-0.25
-0.47
-0.0357
2.34
0.09
0.80
63.60
97.14
0.2857
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
229.13
1.68
8.0
10.0
23.0
59.0
3.0
6.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0285534 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
Cyclization
Cyclization
Bio-Activity Profile
Antimicrobial Antiviral Cytotoxic
MT-2 cells
200 μM
CC50
PaperPubMed PMID: 22406118 PMID22406118 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22406118/
RECORD: Rec_0308275 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
cyclic peptide architecture [Cyclic]
canonical L-amino-acid peptide [L]
Cyclization (N termini to C termini)
Cyclization (N termini to C termini)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 IIIB
8.96±2.23 μM
IC50
Mammalian: 1.2 h; Yeast: >20 h; E. coli: >10 h
PaperShort cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. | Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K. | Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. | DOI:10.1016/j.bmcl.2012.02.037 | PMID:22406118 PMID22406118 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22406118/
RECORD: Rec_0318216 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
cyclic peptide architecture [Cyclic]
canonical L-amino-acid peptide [L]
Cyclization (N termini to C termini)
Cyclization (N termini to C termini)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1
5.95 μM
IC50
Mammalian: 1.2 h; Yeast: >20 h; E. coli: >10 h
PaperShort cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. | Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K. | Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. | DOI:10.1016/j.bmcl.2012.02.037 | PMID:22406118 PMID22406118 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22406118/
RECORD: Rec_0381860 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
cyclic/stapled peptide [Cyclic]
canonical L-amino-acid peptide [L]
Cyclization
Cyclization
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 IIIB:inhibition of virus replication
8.96±2.23 μM
IC50
PaperPubMed PMID: 22406118 PMID22406118 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/22406118/
FIRST PREV 1 2
Showing 4 records on this page · Page 2 of 2